Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 15;134(1):204–215. doi: 10.1213/ANE.0000000000005768

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Anesthesia Research Society.

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

PMC Copyright notice

Figure 2. — Upregulation of neuronal GRK2 altered the proinflammatory activity of spinal microglia and the expression of TREM2/DAP12. Western blot analysis of TREM2 (A) and DAP12 (B) on week 3 after the first cisplatin injection. Results are normalized to β-actin and shown as ratios to saline-treated mice. Values are mean ± SEM. *P < .05, **P < .01. A, Saline versus cisplatin P = .0149; cis + AAV-eGFP versus cis + AAV-GRK2 P = .0187; cisplatin versus cis + AAV-GRK2 P = .0012. B, saline versus cisplatin P = .0482; cis + AAV-eGFP versus cis + AAV-GRK2 P = .0168; cisplatin versus cis + AAV-GRK2 P = .0107. Real-time PCR analysis of pain-related molecules at week 3 after the first cisplatin injection. These molecules were included: IL-1β (C), IL-6 (D), iNOS (E), CD16 (F), IL-4 (G), IL-10 (H), and CD206 (I). Results are normalized to GAPDH. Values are mean ± SEM. *P < .05, **P < .01. C, Saline versus cisplatin P = .0321; cis + AAV-eGFP versus cis + AAV-GRK2 P = .0333; cisplatin versus cis + AAV-GRK2 P = .0054. D, Saline versus cisplatin P = .0078; cis + AAV-eGFP versus cis + AAV-GRK2 P = .0440; cisplatin versus cis + AAV-GRK2 P = .0092. E, Saline versus cisplatin P = .0293; cis + AAV-eGFP versus cis + AAV-GRK2 P = .0218; cisplatin versus cis + AAV-GRK2 P = .0485. F, Saline versus cisplatin P = .0395; cisplatin versus cis + AAV-GRK2 P = .0240. I, Cis + AAV-eGFP versus cis + AAV-GRK2 P = .0392. AAV indicates adeno-associated virus; CD, cluster of differentiation; DAP12, DNAX-activating protein of 12 kDa; eGFP, enhanced green fluorescent protein; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GRK2, G protein–coupled receptor kinase 2; IL, interleukin; iNOS, inducible nitric oxide synthase; PCR, polymerase chain reaction; SEM, standard error of the mean; TREM2, triggering receptor expressed on myeloid cells 2.